Résultats de la recherche - Jingjin Li
- Résultat(s) 1 - 17 résultats de 17
-
1
-
2
-
3
HSPA12B attenuates cardiac dysfunction and remodelling after myocardial infarction through an eNOS-dependent mechanism par Jingjin Li, Yangyang Zhang, Chuanfu Li, Jian Xie, Ying Liu, Weina Zhu, Xiaojin Zhang, Surong Jiang, Li Liu, Zhengnian Ding
Publié 2013Artigo -
4
Enhancer-promoter interaction maps provide insights into skeletal muscle-related traits in pig genome par Jingjin Li, Yue Xiang, Lu Zhang, Xiaolong Qi, Zhuqing Zheng, Peng Zhou, Zhenshuang Tang, Yi Jin, Qiulin Zhao, Yuhua Fu, Yunxia Zhao, Xinyun Li, Liangliang Fu, Shuhong Zhao
Publié 2022Artigo -
5
A compendium and comparative epigenomics analysis of cis-regulatory elements in the pig genome par Yunxia Zhao, Ye Hou, Yueyuan Xu, Yu Luan, Huanhuan Zhou, Xiaolong Qi, Mingyang Hu, Daoyuan Wang, Zhangxu Wang, Yuhua Fu, Jingjin Li, Saixian Zhang, Jianhai Chen, Jianlin Han, Xinyun Li, Shuhong Zhao
Publié 2021Artigo -
6
Genome-scale CRISPR screen identifies TMEM41B as a multi-function host factor required for coronavirus replication par Limeng Sun, Changzhi Zhao, Zhen F. Fu, Yanan Fu, Zhelin Su, Yang Yang Li, Yuan Zhou, Yubei Tan, Jingjin Li, Yixin Xiang, Xiongwei Nie, Jinfu Zhang, Fei Liu, Shuhong Zhao, Shengsong Xie, Guiqing Peng
Publié 2021Artigo -
7
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera par Alessandro M. Vannucchi, Jean‐Jacques Kiladjian, Martin Grießhammer, Tamás Masszi, Simon Durrant, Francesco Passamonti, Claire Harrison, Fabrizio Pane, Pierre Zachée, Ruben A. Mesa, Shui He, Mark M. Jones, William M. Garrett, Jingjin Li, Ulrich Pirron, Dany Habr, Srđan Verstovšek
Publié 2015Artigo -
8
Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy par Ruben A. Mesa, Srđan Verstovšek, Jean‐Jacques Kiladjian, Martin Grießhammer, Tamás Masszi, Simon Durrant, Francesco Passamonti, Claire Harrison, Fabrizio Pane, Pierre Zachée, Hui‐Ling Zhen, Mark M. Jones, Shreekant Parasuraman, Jingjin Li, Isabelle Côté, Dany Habr, Alessandro M. Vannucchi
Publié 2015Artigo -
9
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies par Kyriakos P. Papadopoulos, Melissa L. Johnson, A. Craig Lockhart, Kathleen N. Moore, Gerald S. Falchook, Silvia C. Formenti, Aung Naing, Richard D. Carvajal, Lee S. Rosen, Glen J. Weiss, Rom S. Leidner, Jingjin Li, Anne Paccaly, Minjie Feng, Elizabeth Stankevich, Israel Lowy, Matthew G. Fury, Marka R. Crittenden
Publié 2019Artigo -
10
REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) par Deepu Madduri, Ashley Rosko, Jason Brayer, Jeffrey A. Zonder, William Bensinger, Jingjin Li, Linzhi Xu, Lieve Adriaens, Dhruti Chokshi, Weijiang Zhang, Anita Boyapati, Manish Sharma, Frank Seebach, L. Andres Sirulnik, David M. Weinreich, George D. Yancopoulos, Madhav V. Dhodapkar, Suzanne Lentzsch, Dennis Cooper, Sundar Jagannath
Publié 2020Artigo -
11
Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patie... par Rajat Bannerji, John N. Allan, Jon Arnason, Jennifer R. Brown, Ranjana H. Advani, Stephen M. Ansell, Susan O’Brien, Johannes Duell, Peter Martin, Robin Joyce, Jingjin Li, Dina M. Flink, Min Zhu, David M. Weinreich, George D. Yancopoulos, Andres Sirulnik, Aafia Chaudhry, Srikanth R. Ambati, Max S. Topp
Publié 2020Artigo -
12
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort i... par Rajat Bannerji, Jon Arnason, Ranjana H. Advani, Jennifer R. Brown, John N. Allan, Stephen M. Ansell, Jeffrey A. Barnes, Susan O’Brien, Julio C. Chávez, Johannes Duell, Andreas Rosenwald, Jennifer L. Crombie, Melanie Ufkin, Jingjin Li, Min Zhu, Srikanth R. Ambati, Aafia Chaudhry, Israel Lowy, Max S. Topp
Publié 2022Artigo -
13
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer par Danny Rischin, Marta Gil-Martín, Antonio González‐Martín, Irene Braña, June Y. Hou, Daniel Cho, Gerald S. Falchook, Silvia C. Formenti, Salma K. Jabbour, Kathleen N. Moore, Aung Naing, Kyriakos P. Papadopoulos, Joaquina Baranda, Wen Fury, Minjie Feng, Elizabeth Stankevich, Jingjin Li, N. Alice Yama-Dang, Suk-Young Yoo, Israel Lowy, Melissa Mathias, Matthew G. Fury
Publié 2020Artigo -
14
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer par Ana Oaknin, Bradley J. Monk, Ignace Vergote, Andréia Cristina de Melo, Yong‐Man Kim, Alla S. Lisyanskaya, Vanessa Samouëlian, Hee Seung Kim, Evgeniy A. Gotovkin, Fernanda Damian, Chih‐Long Chang, Shunji Takahashi, Jingjin Li, Melissa Mathias, Matthew G. Fury, Cristina Ivanescu, Matthew Reaney, Patrick R. LaFontaine, Israel Lowy, James Harnett, Chieh-I Chen, Krishnansu S. Tewari
Publié 2022Artigo -
15
Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) par Sabarish Ayyappan, Won Seog Kim, Tae Min Kim, Jan Walewski, Seok‐Goo Cho, Isidro Jarque, Elżbieta Iskierka‐Jażdżewska, Michelle Poon, Sung Yong Oh, Francesca Lim, Cecilia Carpio, Tran‐Der Tan, Antonio Gutiérrez, Huilai Zhang, Junning Cao, Mingzhi Zhang, Benoît Tessoulin, Jingjin Li, Melanie Ufkin, Saleem Shariff, Lei Chi, Aafia Chaudhry, Hesham Mohamed, Srikanth R. Ambati, H. Miles Prince
Publié 2023Artigo -
16
Survival with Cemiplimab in Recurrent Cervical Cancer par Krishnansu S. Tewari, Bradley J. Monk, Ignace Vergote, Austin Miller, Andréia Cristina de Melo, Hee‐Seung Kim, Yong Man Kim, Alla Lisyanskaya, Vanessa Samouëlian, Domenica Lorusso, Fernanda Damian, Chih‐Long Chang, Evgeniy A. Gotovkin, Shunji Takahashi, Daniella Ramone, Joanna Pikiel, Beata Maćkowiak-Matejczyk, Eva Maria Guerra Alía, Nicoletta Colombo, Yulia Makarova, Danny Rischin, Stéphanie Lheureux, Kosei Hasegawa, Keiichi Fujiwara, Jingjin Li, Shaheda Jamil, Vladimir Janković, Chieh-I Chen, Frank Seebach, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Melissa Mathias, Matthew G. Fury, Ana Oaknin
Publié 2022Artigo -
17
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma par Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults, Alexander Guminski, Axel Hauschild, Karl D. Lewis, Christine H. Chung, Leonel F. Hernandez‐Aya, Annette M. Lim, Anne Lynn S. Chang, Guilherme Rabinowits, Alesha Thai, Lara Dunn, Brett Hughes, Nikhil I. Khushalani, Badri Modi, Dirk Schadendorf, Bo Gao, Frank Seebach, Siyu Li, Jingjin Li, Melissa Mathias, Jocelyn Booth, Kosalai Kal Mohan, Elizabeth Stankevich, Hani M. Babiker, Irene Braña, Marta Gil-Martín, Jade Homsi, Melissa L. Johnson, Víctor Moreno, Jiaxin Niu, Taofeek K. Owonikoko, Kyriakos P. Papadopoulos, George D. Yancopoulos, Israel Lowy, Matthew G. Fury
Publié 2018Artigo
Outils de recherche:
Sujets similaires
Medicine
Internal medicine
Oncology
Biology
Cancer
Gene
Adverse effect
Astrobiology
Cervical cancer
Clinical endpoint
Clinical trial
Gastroenterology
Genetics
Genome
Lymphoma
Refractory (planetary science)
Rituximab
Applied psychology
Archaeology
Bone marrow
Chemotherapy
Chimeric antigen receptor
Cohort
Computational biology
Cytokine release syndrome
Environmental health
Follicular lymphoma
Gene expression
Immunotherapy
Myelofibrosis